Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 1,652 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia Spectrum and Other Psychotic Disorders Clear all
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Craving in Nicotine-Dependent Patients With Schizophrenia Using Virtual Reality

NCT01031433
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?

NCT01964404
View directory record Official record
Conditions
Schizophrenia, Dual Diagnosis, Psychotic Disorder, Cannabis Use Disorder
Interventions
Marijuana, Dronabinol, Placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
263 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
2
States / cities
Lebanon, New Hampshire • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 18, 2026, 5:40 AM EDT
Active, not recruiting Not applicable Interventional

Promoting Activity and Cognitive Enrichment in Schizophrenia (PACES)

NCT04143126
View directory record Official record
Conditions
Schizophrenia
Interventions
Cognitive Enhancement Therapy, Enriched Supportive Therapy
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Phase 1 Interventional Results available

A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia

NCT01829048
View directory record Official record
Conditions
Schizophrenia
Interventions
PF-02545920, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 18, 2026, 5:40 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Glutamatergic Mechanisms of Psychosis and Target Engagement (SA1)

NCT04589208
View directory record Official record
Conditions
Healthy
Interventions
Ketamine Hydrochloride
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Phase 4 Interventional Results available

An Efficacy and Safety Study of One Dosage of Paliperidone Extended Release (ER) in Treating Patients With Schizophrenia

NCT00524043
View directory record Official record
Conditions
Schizophrenia
Interventions
Paliperidone ER, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Cerritos, California • Torrance, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Oct 18, 2026, 5:40 AM EDT
Terminated Phase 4 Interventional

Extended Duration Nicotine Replacement Therapy and Bupropion in Smokers With Schizophrenia

NCT01576640
View directory record Official record
Conditions
Nicotine Dependence, Schizophrenia
Interventions
NRT, Bupropion SR 150mg bid, Relapse Prevention-Oriented Cognitive Behavioral Therapy
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Oct 18, 2026, 5:40 AM EDT
Recruiting Phase 1 Interventional

A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia

NCT07615426
View directory record Official record
Conditions
Schizophrenia
Interventions
Aticaprant, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
Garden Grove, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Phase 4 Interventional Results available

Lurasidone Effects on Tissue Glutamate in Schizophrenia

NCT02199743
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Lurasidone, Haloperidol, Perphenazine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Phase 1 Interventional

A Safety and PK Study of Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Schizophrenia

NCT01592110
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone-SABER, ZX003:risperidone-SABER and the DosePro System
Drug · Other
Lead sponsor
Zogenix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2022 · Synced Oct 18, 2026, 5:40 AM EDT
Available No phase listed Expanded access

An Expanded Access Program (EAP) for OLZ/SAM in Pediatric Participants With Schizophrenia or Bipolar I Disorder (ALKS 3831-315)

NCT07744113
View directory record Official record
Conditions
Bipolar 1 Disorder, Schizophrenia Disorder
Interventions
OLZ/SAM
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
10 Years to 17 Years
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Phase 4 Interventional Results available

Biomarker Study of Acamprosate in Schizophrenia

NCT00688324
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Acamprosate
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Not applicable Interventional

Medication Adherence in Older Adults With Serious Mental Illness

NCT00224380
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Depression
Interventions
Using Medications Effectively
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
50 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Nashua, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 23, 2009 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Phase 3 Interventional Results available

Brexpiprazole in Patients With Acute Schizophrenia

NCT01810380
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Brexpiprazole, Quetiapine extended release
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Escondido, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Not applicable Interventional

STEP-ED: Reducing Duration of Untreated Psychosis and Its Impact in the U.S.

NCT02069925
View directory record Official record
Conditions
Psychosis, Schizophrenia
Interventions
Early Detection (ED), Usual Detection
Behavioral
Lead sponsor
Yale University
Other
Eligibility
16 Years to 35 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
New Haven, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Nicotinic Receptors and Schizophrenia

NCT00952393
View directory record Official record
Conditions
Schizophrenia
Interventions
Pharmacokinetic
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 5, 2016 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Phase 4 Interventional Results available

Trial of Nicotine Nasal Spray as an Aid for Smoking Cessation in Schizophrenia

NCT01010477
View directory record Official record
Conditions
Smoking Cessation, Schizophrenia
Interventions
Nicotine Nasal Spray, Behavioral counseling
Drug · Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Not applicable Interventional Results available

Home-based Transcranial Direct Current Stimulation (tDCS) for Behavioral Symptoms in Alzheimer's Disease and Related Dementias (ADRD)

NCT05478681
View directory record Official record
Conditions
Alzheimer Disease
Interventions
active tDCS
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
60 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 18, 2026, 5:40 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

ERG Components in Schizophrenia and Bipolar Disorder Type I

NCT03788811
View directory record Official record
Conditions
Schizophrenia, Bipolar I Disorder
Interventions
ERG assessment (RSPA)
Device
Lead sponsor
diaMentis Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
11
States / cities
Garden Grove, California • Lemon Grove, California • Torrance, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Not applicable Interventional Results available

Person-Centered Versus Measurement-Based Care in Mental Health

NCT02507349
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Major Depression
Interventions
Person-Centered Care, Measurement-Based Care
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
2,443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Lebanon, New Hampshire • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 18, 2026, 5:40 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Direct Measurements of Cardiometabolic Risk in Treated Schizophrenia Patients

NCT00501163
View directory record Official record
Conditions
Schizophrenia, Cardiovascular Disease
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
10 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Not applicable Interventional Results available

Cognitive Behavioral Suicide Prevention for Psychosis: Aim 2

NCT05345184
View directory record Official record
Conditions
Suicide, Psychosis
Interventions
Cognitive Behavioral Suicide Prevention for psychosis (CBSPp), Services as Usual (SAU)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Phase 4 Interventional

Injectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness (SMI)

NCT00453804
View directory record Official record
Conditions
Bipolar Disorders, Schizophrenia, Schizoaffective Disorders, Alcohol Dependence
Interventions
injectable naltrexone, oral naltrexone
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 69 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2008 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia

NCT00802100
View directory record Official record
Conditions
Schizophrenia
Interventions
Olanzapine, Perphenazine, Aripiprazole, Metformin, Simvastatin, Benztropine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 40 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
13
States / cities
Colton, California • Palo Alto, California • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 18, 2026, 5:40 AM EDT